Drug Trial Radar · NCT04033367
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Aug 22, 2019
Primary completion
Oct 6, 2021
Study completion Oct 6, 2021
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jul 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD). Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation. To continue to assess the safety and tolerability throughout the study.
Conditions
- Atopic Dermatitis
Interventions
DupilumabDrug
Pharmaceutical form: solution for injection Route of administration: subcutaneous
PlaceboDrug
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12Time frame: Baseline, Week 12
Locations
42 sites in 10 countries. Site status is shown where the registry gives one.
Investigational Site Number :8400012
North Little Rock, Arkansas
Investigational Site Number :8400002
Redwood City, California
Investigational Site Number :8400001
Rolling Hills Estates, California
Investigational Site Number :8400013
Colorado Springs, Colorado
Investigational Site Number :8400005
Denver, Colorado
Investigational Site Number :8400003
Sarasota, Florida
Investigational Site Number :8400007
Medford, Oregon
Investigational Site Number :8400008
Charleston, South Carolina
Investigational Site Number :0360006
Phillip, Australian Capital Territory, Australia
Investigational Site Number :0360001
Kogarah, New South Wales, Australia
Investigational Site Number :0360007
Woolloongabba, Queensland, Australia
Investigational Site Number :0360003
Carlton, Victoria, Australia
Investigational Site Number :2500001
Brest, France
Investigational Site Number :2500003
Nantes, France
Investigational Site Number :2500002
Paris, France
Investigational Site Number :2500006
Toulouse, France
Investigational Site Number :2760005
Bad Bentheim, Germany
Investigational Site Number :2760002
Frankfurt am Main, Germany
Investigational Site Number :2760006
Friedrichshafen, Germany
Investigational Site Number :2760001
Göttingen, Germany
Investigational Site Number :2760004
Münster, Germany
Investigational Site Number :3760005
Afula, Israel
Investigational Site Number :3760003
Jerusalem, Israel
Investigational Site Number :3800006
Perugia, Italy
Investigational Site Number :3800001
Pisa, Italy
Investigational Site Number :3800004
Reggio Calabria, Italy
Investigational Site Number :3800002
Roma, Italy
Investigational Site Number :3800003
Siena, Italy
Investigational Site Number :3800005
Rozzano, Milano, Italy
Investigational Site Number :7240006
Córdoba, Spain
Investigational Site Number :7240008
Madrid, Spain
Investigational Site Number :7240010
Madrid, Spain
Investigational Site Number :7240005
Seville, Spain
Investigational Site Number :7240002
Valencia, Spain
Investigational Site Number :7240004
Granada, Andalusia, Spain
Investigational Site Number :7240001
Barcelona / Sabadell, Castille and León, Spain
Investigational Site Number :7240003
Manises, Valencia, Spain
Investigational Site Number :7560001
Bern, Switzerland
Investigational Site Number :7840002
Abu Dhabi, United Arab Emirates
Investigational Site Number :7840001
Dubai, United Arab Emirates
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.